CRIS Quote, Financials, Valuation and Earnings

Enzon Pharmaceuticals, Inc. has a net margin of -243.36% compared to Curis, Inc.'s net margin of --. Curis, Inc.'s return on equity of -461.34% beat Enzon Pharmaceuticals, Inc.'s return on equity of -5.37%.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1161.26%. On the other hand Enzon Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Curis, Inc. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe Curis, Inc. is more attractive than Enzon Pharmaceuticals, Inc..

Curis, Inc. has a beta of 3.078, which suggesting that the stock is 207.818% more volatile than S&P 500. In comparison Enzon Pharmaceuticals, Inc. has a beta of 0.196, suggesting its less volatile than the S&P 500 by 80.447%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enzon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. Enzon Pharmaceuticals, Inc. pays out -163.88% of its earnings as a dividend.

Curis, Inc. quarterly revenues are $3.2M, which are larger than Enzon Pharmaceuticals, Inc. quarterly revenues of --. Curis, Inc.'s net income of -$7.7M is lower than Enzon Pharmaceuticals, Inc.'s net income of -$824K. Notably, Curis, Inc.'s price-to-earnings ratio is -- while Enzon Pharmaceuticals, Inc.'s PE ratio is 96.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.06x versus 225.50x for Enzon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LadRx Corp. has a net margin of -243.36% compared to Curis, Inc.'s net margin of --. Curis, Inc.'s return on equity of -461.34% beat LadRx Corp.'s return on equity of --.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1161.26%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 408990.91%. Given that LadRx Corp. has higher upside potential than Curis, Inc., analysts believe LadRx Corp. is more attractive than Curis, Inc..

Curis, Inc. has a beta of 3.078, which suggesting that the stock is 207.818% more volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.

Curis, Inc. quarterly revenues are $3.2M, which are larger than LadRx Corp. quarterly revenues of --. Curis, Inc.'s net income of -$7.7M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Curis, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.06x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -243.36% compared to Curis, Inc.'s net margin of -316.61%. Curis, Inc.'s return on equity of -461.34% beat Plus Therapeutics, Inc.'s return on equity of --.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1161.26%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1595.96%. Given that Plus Therapeutics, Inc. has higher upside potential than Curis, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Curis, Inc..

Curis, Inc. has a beta of 3.078, which suggesting that the stock is 207.818% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Curis, Inc. quarterly revenues are $3.2M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Curis, Inc.'s net income of -$7.7M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Curis, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.06x versus 5.20x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Windtree Therapeutics, Inc. has a net margin of -243.36% compared to Curis, Inc.'s net margin of --. Curis, Inc.'s return on equity of -461.34% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1161.26%. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 37635.85%. Given that Windtree Therapeutics, Inc. has higher upside potential than Curis, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Curis, Inc..

Curis, Inc. has a beta of 3.078, which suggesting that the stock is 207.818% more volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Curis, Inc. quarterly revenues are $3.2M, which are larger than Windtree Therapeutics, Inc. quarterly revenues of --. Curis, Inc.'s net income of -$7.7M is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Curis, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.06x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.